Immunocompatible chorionic membrane products
Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.
1. A cryopreserved chorionic membrane comprising viable cells native to the chorionic membrane; wherein the cryopreserved chorionic membrane is immunocompatible; wherein at least about 70% of the cells are viable; wherein the viable cells comprise at least two cell types consisting of mesenchymal stem cells (MSCs) and fibroblasts; and wherein the cryopreserved chorionic membrane comprises CD14+ macrophages in an amount of less than about 5%.
2. The cryopreserved chorionic membrane of claim 1 , wherein the cryopreserved chorionic membrane comprises one or more therapeutic factors native to the chorionic membrane.
3. The cryopreserved chorionic membrane of claim 1 , wherein the cryopreserved chorionic membrane comprises extracellular matrix that is native to the chorionic membrane.
4. The cryopreserved chorionic membrane of claim 1 , wherein the chorionic membrane is made immunocompatible by removal of all or a portion of a trophoblast layer.
5. The cryopreserved chorionic membrane of claim 1 , wherein the chorionic membrane exhibits a substantial decrease in TNF-α release after lipopolysaccharide (LPS) stimulation.
6. The cryopreserved chorionic membrane of claim 5 , wherein the chorionic membrane releases less than 420 pg/ml of TNF-a.
7. The cryopreserved chorionic membrane of claim 1 , wherein the chorionic membrane is substantially free of immunogenic maternal cells.
8. The cryopreserved chorionic membrane of claim 7 , wherein the maternal cells are maternal dendritic cells, maternal leukocytes, or combinations thereof.
9. The cryopreserved chorionic membrane of claim 1 , wherein the viable cells comprise stromal cells.
10. The cryopreserved chorionic membrane of claim 9 , wherein the stromal cells are present in an amount of about 5,000 per cm 2 to about 50,000 per cm 2 of the chorionic membrane.
11. The cryopreserved chorionic membrane of claim 1 , further comprising at least one cell-permeating cryopreservative, at least one non-cell-permeating cryopreservative, derivatives thereof, or a combination thereof.
12. The cryopreserved chorionic membrane of claim 11 , wherein the cell-permeating cryopreservative, the non-cell-permeating cryopreservative, derivative thereof, or combination thereof is present in an amount of about 5% to about 20% by volume.
13. The cryopreserved chorionic membrane of claim 12 , wherein the cell-permeating cryopreservative is DMSO.
14. The cryopreserved chorionic membrane of claim 1 , wherein the chorionic membrane comprises fibroblasts present in an amount of about 50% to about 90% of the total cells, and wherein at least about 40% of the fibroblasts are viable after one freeze-thaw cycle.
15. The cryopreserved chorionic membrane of claim 1 , wherein the chorionic membrane comprises mesenchymal stem cells in an amount of about 5% to about 30% and wherein at least 40% of the MSCs are viable after one freeze-thaw cycle.
16. The cryopreserved chorionic membrane of claim 1 , wherein the chorionic membrane comprises a whole or partial basement membrane, a whole or partial reticular layer, or a whole or portion combination thereof.
17. The cryopreserved chorionic membrane of claim 1 , wherein the chorionic membrane is associated with a nitrocellulose substrate or support.
18. A membrane comprising cryopreserved chorionic membrane, wherein the cryopreserved chorionic membrane comprises:
a) a chorionic membrane;
b) viable cells, wherein said viable cells are native to the chorionic membrane and greater than 70% of said cells are viable, wherein the viable cells comprise at least two cell types consisting of MSCs and fibroblasts;
c) one or more therapeutic factors that is native to the chorionic membrane;
d) extracellular matrix that is native to the chorionic membrane; and
e) an amount of less than about 5% of CD14+ macrophages.
19. The membrane of claim 18 , further comprising a cryopreserved amniotic membrane wherein the amniotic membrane comprises a layer of amniotic epithelial cells.
20. The membrane of claim 19 , wherein the cryopreserved chorionic membrane is substantially depleted of placental trophoblasts.
21. A method of treating an injury comprising administering to the injury the cryopreserved chorionic membrane of claim 1 when thawed.
22. The method of claim 21 , wherein the injury is a wound.
23. The method of claim 22 , wherein the wound is a laceration, a scrape, a thermal or chemical burn, an incision, a puncture, a wound caused by a projectile, an epidermal wound, a skin wound, a chronic wound, an acute wound, an external wound, an internal wound, a congenital wound, an ulcer, a pressure ulcer, or a combination thereof.
24. The method of claim 21 , wherein the injury comprises a wound or injury associated with a surgical procedure.
25. The method of claim 24 , wherein the surgical procedure is selected from the group consisting of a tendon surgery, a ligament surgery, a bone surgery, a spinal surgery, a laminectomy, a knee surgery, a shoulder surgery, and child delivery.